FDA delays decision on GSK blood cancer drug at heart of $1.9B Sierra Oncology deal
GSK’s blood cancer drug momelotinib has taken another turn on its winding journey, with the FDA delaying its review of the investigational tablet that GSK picked up in last year’s buyout of Sierra Oncology by three months.
GSK said Friday that the regulator pushed back its decision, originally slated for June 16, to Sept. 16, to “provide time to review recently submitted data.”
“GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalize their review,” the company said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.